Collaboration and License Agreements (Details) - USD ($) |
12 Months Ended | |||
---|---|---|---|---|
Feb. 05, 2018 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2003 |
|
Other income | $ 368,750 | |||
Upfront payment | $ 3,000,000 | |||
Revenue recognized | 0 | |||
Deferred revenue | 1,500,000 | |||
Amount due | 1,500,000 | |||
Fixed consideration | 3,000,000 | |||
RX-3117 License [Member] | ||||
Upfront payment | 2,500,000 | |||
RX-3117 Clinical Material [Member] | ||||
Upfront payment | $ 500,000 | |||
RX-0201 [Member] | ||||
Other income | $ 368,750 | |||
Research and development period | 20 years | |||
Reduction of research and development expenses | $ 6,250 | |||
Research and development arrangement, one-time fee | $ 1,500,000 | |||
Percentage of licensing revenue | 50.00% | |||
Licensing revenue agreement | $ 5,000,000 | |||
China [Member] | ||||
Milestone payment | $ 126,000,000 | |||
Republic of Singapore, China, Hong Kong, Macau and Taiwan [Member] | ||||
Milestone payment | $ 100,000,000 |
X | ||||||||||
- Definition Collaborative Arrangement, Milestone Payment No definition available.
|
X | ||||||||||
- Definition Fixed Contingent Consideration No definition available.
|
X | ||||||||||
- Definition Licensing Revenue Agreement No definition available.
|
X | ||||||||||
- Definition Licensing Revenue Agreement, Percent No definition available.
|
X | ||||||||||
- Definition Research And Developement Agreement Period No definition available.
|
X | ||||||||||
- Definition Research And Developement Agreement Period Expense Reduction Amount No definition available.
|
X | ||||||||||
- Definition Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|